TEL AVIV (VINnews) — Nvidia has launched a new research group in Israel that will use artificial intelligence to speed work in medicine, drug development and related science, Israeli news outlets reported Wednesday.
Join our WhatsApp groupSubscribe to our Daily Roundup Email
The unit, called Applied AI Architecture, sits inside Nvidia’s Israeli development center and reports through the office of Chief Technology Officer Michael Kagan, a co-founder of Mellanox Technologies, which Nvidia acquired in 2020. The group is led by Dr. Nati Daniel, who earned a doctorate in artificial intelligence from the Technion-Israel Institute of Technology and previously worked at Intel, GE and Huawei.
The team already has several researchers in Israel and plans to hire dozens more over the next year at Nvidia offices in Tel Aviv, where related research jobs have been posted. Officials described the mandate as long-term scientific work rather than short-term product development, with the aim of turning AI into a tool that can shorten the path from data to treatments.
One early project is a genomic foundation model being developed with Sheba Medical Center in Israel and Mount Sinai in New York. Researchers say the model is meant to help study the large share of the human genome that remains poorly understood and to link genetic variation with disease risk and treatment response. Nvidia is providing computing systems, software and AI expertise; the medical centers are contributing genomic and clinical data.
The Israeli group is also tied to Nvidia’s broader drug-discovery work with Eli Lilly and Co. The companies have said they plan to invest about $1 billion over five years to apply AI to genomic, chemical and biological data in hopes of moving candidate drugs forward more quickly. Reports also said the unit is involved in materials research, including work connected to a European project on advanced materials.
Israel is Nvidia’s largest research and development base outside the United States. The company’s local footprint grew sharply after the Mellanox deal and now includes multiple centers and thousands of employees. Company leaders have cited Israel’s mix of AI talent and medical research institutions as a reason to expand applied science work there.
Nvidia has not issued a detailed public timeline for first clinical or commercial results from the new lab. Partners have said the genomic model and related tools are intended, over time, to support earlier diagnosis, more targeted drugs and faster movement of research into patient care.
